Recently, QINGDAO AMA Co.,LTD. Company has been on the move, consecutively appearing at industry events in Beijing and Shanghai. It has established deep connections with national-level industrial resources, focused on cutting-edge cell and gene therapy (CGT) technologies, and actively promoted the integration of sports and healthcare with industrial transformation. This demonstrates its forward-looking strategy and dynamic presence in the golden track of life sciences and health.

Beijing Stop: Industrial Hub Inauguration, Building Resource Ecosystems

On December 11, a series of events co-hosted by the Qingdao Biomedical Industry Association, Qingdao Science and Technology Bureau, Qingdao Hi-Tech Zone, China Biomedical Park Committee (CBPCA), and the Institute of Sport Science under the General Administration of Sport of China concluded successfully in Beijing.The highly anticipated "Chain National · Beijing Station" for Qingdao's life sciences industry officially debuted during the event. This platform aims to connect industrial resources between Beijing and Qingdao, facilitating in-depth collaboration and partnerships.

As a key participant, QINGDAO AMA Co.,LTD. Company signed a strategic agreement with CBPCA at the event, marking a crucial step in integrating into the national biomedical industry network and accessing high-end platform resources. The concurrently held CGT Industry Symposium gathered guests from the China Anti-Aging Association, the Chinese Medical Doctor Association, and multiple investment institutions, fostering intellectual exchange and consensus building.

That afternoon, the company participated in the CGT-themed roadshow with its "Stentless Cell Sheet Technology" project. The project's cutting-edge concepts and technical approach garnered significant attention from attending experts and investment institutions. The valuable suggestions and clear direction provided will inject accelerated momentum into the technology's subsequent development and commercialization.

On December 12， The "Chain National · Beijing Station" was officially launched at the National Sports Science Institute's Guoti Yao Yan Joint Laboratory under the General Administration of Sport of China, focusing on the fields of "sports-medicine integration" and "active health."Attendees included Xing Jun, Deputy Director of Qingdao Municipal Science and Technology Bureau; Zhou Xin, Deputy Director of Qingdao Hi-Tech Zone Administrative Committee; Zhang Zhixiang, Executive President of Guoyan Think Tank; and Shang Xiaoqun, Executive Director of Guoti Smart Sports Technology Innovation Center. QINGDAO AMA Co.,LTD. Company representatives toured the innovation product exhibition, gaining firsthand insights into cutting-edge trends in technology-enabled health solutions.

Shanghai Station: Focusing on Precision Integration, Gaining Insights into the Future of CGT

On December 14, QINGDAO AMA Co.,LTD. was invited to attend the "2025 Precision Medicine and Cellular Gene Therapy Conference" held in Shanghai. Centered on the theme "Precision Integration, Cellular Empowerment," the conference gathered over 500 industry experts and scholars.

During the event, nearly 30 high-level presentations were delivered, delving into the latest breakthroughs and translation pathways from laboratory research to clinical applications. Company representatives gained significant insights through exchanges with industry leaders, further solidifying their commitment to pushing the boundaries of life through innovation and gaining clearer perspectives on the future trajectory of the CGT field.

Conclusion

From industrial resource networking and strategic agreements in Beijing to insights into international cutting-edge trends in Shanghai; from CGT technology roadshows to deepening understanding of the national "Integration of Sports and Healthcare" strategy—within just a few days, QINGDAO AMA Co.,LTD.n completed an efficient journey of industrial interaction and learning.

Moving forward, QINGDAO AMA Co.,LTD. will continue leveraging high-end platforms like "Chain National" to deepen collaborations with research institutions, industry associations, and investment communities. The company remains committed to monitoring and engaging in cutting-edge life science fields such as cell therapy, dedicated to advancing the translation of innovative technologies into practical applications and contributing positively to the advancement of human health.